For further information about the development and research behind TheraTarget’s technology, we welcome you to review these publications:
“Combination treatment with immunogenic and anti-PD-L1 polymer-drug conjugates of advanced tumors in a transgenic MMTV-PyMT mouse model of breast cancer.” February 6, 2021
“Polymer nanomedicines” July 28, 2020
“Inhibition of Immunosuppressive Tumors by Polymer-Assisted Inductions of Immunogenic Cell Death and Multivalent PD-L1 Crosslinking” March 17, 2020
“The Light at the End of the Tunnel—Second Generation HPMA Conjugates for Cancer Treatment” September 1, 2017
“Indium-based and iodine-based labeling of HPMA copolymer– epirubicin conjugates: Impact of structure on the in vivo fate” August 10,2016